Navitas Semiconductor's shares rose 12% premarket after securing a U.S. Army contract to develop next-generation silicon carbide power semiconductor technology. This project aims to create a domestic manufacturing process for ultra-high-voltage silicon carbide devices, marking a milestone in power semiconductor innovation. Meanwhile, Eli Lilly plans larger acquisitions in infectious disease, women's health, and mental health to fuel growth. Additionally, a federal judge allowed Monsanto's patent lawsuit against Pfizer, BioNTech, and Moderna over mRNA technology to proceed, increasing legal risks for these companies. AstraZeneca also invested $2 billion in Summit Therapeutics for cancer treatment development, boosting Summit's shares by 24%.
Summit Therapeutics shares surged 17.89% on Pluang, trading at USD 18.25 as of Sep 29, 2026 18:14 WIB, reflecting strong investor interest following AstraZeneca's $2 billion investment. Meanwhile, Eli Lilly's stock is slightly down 0.07% at USD 1,185.19, and Pfizer is up 0.21% at USD 28.79, showing mixed reactions in the health sector. BioNTech and Moderna saw declines of 0.37% and 0.98% respectively on Pluang at the same time.
Eli Lilly's Foundayo (orforglipron) 17.2 mg showed significantly greater weight loss (1.5% more) and A1C reduction (0.3% more) than oral semaglutide 25 mg after 52 weeks in adults with type 2 diabetes, based on an indirect comparison of ACHIEVE-3 and...
Eli Lilly launched the 'Change the Course Commitment' aiming to treat as many diabetes and obesity patients in low- and middle-income countries (LMICs) as in high-income countries by 2040. Currently, only one in four patients in LMICs have access to ...
The FDA approved Eli Lilly's Onswik, a once-weekly basal insulin for adults with type 2 diabetes, marking a useful extension to its diabetes treatments. While the stock rose 2.85% to $1,183.76, this new insulin is unlikely to significantly change the...
The FDA has approved Olumiant (baricitinib), a once-daily pill, for treating severe alopecia areata (AA) in pediatric patients aged 12 and older. This approval is based on positive results from the BRAVE-AA-PEDS Phase 3 study, showing significant sca...
Novo Nordisk revealed a strategy to boost growth beyond its top obesity drugs Wegovy and Ozempic, facing patent expirations in the early 2030s. Despite promising a pipeline of new drugs, investors remain skeptical as Eli Lilly gains market share, esp...
